Protox Therapeutics, a developer of receptor targeted fusion proteins, has appointed John Parkinson as its new CFO.
Subscribe to our email newsletter
Mr Parkinson will replace David Swetlow, vice president of finance and operations, who is leaving Protox to pursue entrepreneurial opportunities.
Previously, Mr Parkinson was vice president of finance at Aspreva Pharmaceuticals. Mr Parkinson is a graduate of the University of Saskatchewan where he received a bachelor of commerce and bachelor of arts in economics.
Fahar Merchant, president and CEO of Protox, said: “John has proven leadership capabilities, business acumen and a track record of successfully managing change and delivering profitable growth. His wealth of knowledge and experience in the US and Canadian capital markets, managing sizable partnership relationships, as well as his thorough understanding of business operations, will provide tremendous depth to our management team.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.